Growth Hormone Secreting Pituitary Adenoma
Mostrando 1-9 de 9 artigos, teses e dissertações.
-
1. Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells
Pituitary adenoma is one of the most common tumors in the neuroendocrine system. This study investigated the effects of long non-coding RNAs (lncRNAs) highly up-regulated in liver cancer (HULC) on rat secreting pituitary adenoma GH3 cell viability, migration, invasion, apoptosis, and hormone secretion, as well as the underlying potential mechanisms. Cell tra
Braz J Med Biol Res. Publicado em: 15/04/2019
-
2. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly
Pituitary adenomas account for 10–15% of primary intracranial tumors. Growth hormone (GH)-secreting adenomas account for 13% of all pituitary adenomas and cause acromegaly. These tumors can be aggressive, invade surrounding structures and are highly recurrent. The objective of this study was to evaluate E-cadherin, Slug and neural cell adhesion molecule (N
Braz J Med Biol Res. Publicado em: 11/12/2017
-
3. Análise do gene AIP na acromegalia familial isolada / Analysis of the AIP gene in familial isolated acromegaly
Acromegaly is a rare disfigurating and insidious disease characterized by enlargement of hands, feet and skull bones due to excess of growth hormone (GH) secreted by a pituitary tumor (somatotropinoma). The majority of the cases with acromegaly is sporadic, however it may occur in association with inherited disorders as Multiple Endocrine Neoplasia type 1 (M
Publicado em: 2010
-
4. Papel da via lkaros-FGFR4 na evolução pós-cirúrgica dos pacientes com doença de Cushing / Ikaros-FGFR4 pathway: role in the postoperative outcome of Cushings disease
Introduction: The mechanisms involved in the molecular pathogenesis of corticotroph pituitary tumors are complex, heterogeneous and in most cases remain unknown. Changes in the expression of components of Ikaros (Ik) pathway, such as receptor 4 of fibroblast growth factor (FGFR4), have been detected in pituitary tumors including corticotropinomas. Imbalance
Publicado em: 2010
-
5. Somatostatin analogs in acromegaly: comparison of clinic response, laboratory and tumor volume with expression of somatostatin receptor subtype in somatotroph tumor / Análogos da somatostatina na acromegalia: comparação da resposta clínica, laboratorial e do volume tumoral com a expressão dos subtipos dos receptores de somatostatina no tumor somatotrófico
Este estudo analisa a expressão dos subtipos de receptores da somatostatina (SSTR) em 39 adenomas secretores de GH. Em 19 pacientes acromegálicos, a resposta clínica, laboratorial e radiológica ao análogo da somatostatina (AS) octreotide-LAR foi comparada à expressão dos SSTR. O SSTR mais freqüentemente expresso foi o SSTR5, seguido pelos SSTR3, SSTR
Publicado em: 2008
-
6. PPAR-γ receptor ligands: novel therapy for pituitary adenomas
Pituitary tumors cause considerable morbidity due to local invasion, hypopituitarism, or hormone hypersecretion. In many cases, no suitable drug therapies are available, and surgical excision is currently the only effective treatment. We show here abundant expression of nuclear hormone receptor PPAR-γ in all of 39 human pituitary tumors. PPAR-γ activating
American Society for Clinical Investigation.
-
7. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Previously, we have shown somatostatin receptor (SSTR) subtype-specific regulation of growth hormone (GH), thyroid-stimulating hormone, and prolactin (PRL) secretion in human fetal pituitary cultures, where GH and thyroid-stimulating hormone are mediated by both SSTR2 and SSTR5, whereas SSTR2 preferentially mediates PRL secretion. We now tested SSTR subtype-
-
8. Somatotroph Hyperplasia: SUCCESSFUL TREATMENT OF ACROMEGALY BY REMOVAL OF A PANCREATIC ISLET TUMOR SECRETING A GROWTH HORMONE-RELEASING FACTOR
A 21-yr-old woman with Turner's syndrome presented with signs and symptoms of acromegaly. The serum growth hormone (GH) (95±9.4 ng/ml; mean±SEM) and somatomedin C (11 U/ml) levels were elevated, and an increase in GH levels after glucose instead of normal suppression, increase after thyrotropin-releasing hormone (TRH) administration instead of no change, a
-
9. Localization of prolactin in chromophobe pituitary adenomas: study of human necropsy material by immunoperoxidase technique.
In order to identify prolactin-producing tumours in human pituitary glands, 45 chromophobe adenomas, obtained from unselected necropsies, have been studied by various staining procedures including the immunoperoxidase technique for the demonstration of prolactin. The presence of immunoreactive prolactin was revealed in the cytoplasm of the tumour cells in si